10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2010 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 18, 2011) | |||
| (In Millions, except shares in Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Net Sales | $ 35,167 | 30,765 | 29,528 |
| Cost of products sold | 14,665 | 13,209 | 12,612 |
| Research and development | 3,724 | 2,744 | 2,689 |
| Acquired in-process research and development | 313 | 170 | 97 |
| Selling, general and administrative | 10,376 | 8,406 | 8,436 |
| Total Operating Cost and Expenses | 29,079 | 24,529 | 23,834 |
| Operating Earnings | 6,088 | 6,236 | 5,694 |
| Interest expense | 553 | 520 | 528 |
| Interest (income) | (105) | (138) | (201) |
| (Income) from the TAP Pharmaceutical Products Inc. joint venture | (119) | ||
| Net foreign exchange (gain) loss | (11) | 36 | 84 |
| Other (income) expense, net | (62) | (1,375) | (455) |
| Earnings from Continuing Operations Before Taxes | 5,713 | 7,194 | 5,856 |
| Taxes on Earnings from Continuing Operations | 1,087 | 1,448 | 1,122 |
| Earnings from continuing operations | 4,626 | 5,746 | 4,734 |
| Gain on Sale of Discontinued Operations, net of taxes | 147 | ||
| Net Earnings | 4,626 | 5,746 | 4,881 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 2.98 | 3.71 | 3.06 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.10 | ||
| Net Earnings (in dollars per share) | 2.98 | 3.71 | 3.16 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations | 2.96 | 3.69 | 3.03 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.09 | ||
| Net Earnings | 2.96 | 3.69 | 3.12 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,546,400 | 1,546,983 | 1,545,355 |
| Dilutive Common Stock Options and Awards (in shares) | 9,622 | 8,143 | 15,398 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,556,022 | 1,555,126 | 1,560,753 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 29,403 | 66,189 | 30,579 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |